

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA499)

NICE GUIDANCE ISSUED DECEMBER 2017

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 1917 – October 2017

Glecaprevir/pibrentasvir (Maviret[®]) 100 mg/40 mg film-coated tablets

Submission by AbbVie Ltd

Recommendation of AWMSG

Glecaprevir/pibrentasvir (Maviret[®]) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in adults.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- AWMSG recommend that glecaprevir/pibrentasvir (Maviret[®]) is used in accordance with the All Wales hepatitis C roll out programme.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3007), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –1917:
Glecaprevir/pibrentasvir (Maviret®) 100 mg /40 mg film-coated tablets. October 2017

